Canada: Pharmaceutical divestment forces conglomerate to revise financial outlook
A major Canadian conglomerate has announced its plans to divest its pharmaceutical company and sell the business to Kohl & Frisch Limited for between $80 million and $100 million. AmerisourceBergen Corporation will divest AmerisourceBergen Canada Corporation to the fulltime distributor in a deal that the parties expect to finalize in the year’s third fiscal quarter. ABCC represented about 2 percent of AmerisourceBergen’s total revenues; due to the transaction the company will reportedly revise its planned financial performance expectations.
Full Content: Fort Mill Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Australia’s Major Supermarkets Face Scrutiny Over Profit Margins Amid Rising Prices
Mar 21, 2025 by
CPI
Fired FTC Commissioners Warn of Potential White House Influence Over Mergers
Mar 20, 2025 by
CPI
Dr. Matthew Backus Joins Compass Lexecon as an Affiliate
Mar 20, 2025 by
CPI
UK to Boost Broadband Competition While Capping Openreach Charges, Says Ofcom
Mar 20, 2025 by
CPI
Singapore Competition Watchdog Yet to Receive Formal Notification on Grab-GoTo Merger
Mar 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li